| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8778924 | PRAGMA | Modified release amoxicillin products |
Dec, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357394 | PRAGMA | Compositions and methods for improved efficacy of penicillin-type antibiotics |
Dec, 2026
(3 years from now) | |
| US8299052 | PRAGMA | Pharmaceutical compositions and methods for improved bacterial eradication |
May, 2027
(3 years from now) | |
Moxatag is owned by Pragma.
Moxatag contains Amoxicillin.
Moxatag has a total of 3 drug patents out of which 0 drug patents have expired.
Moxatag was authorised for market use on 23 January, 2008.
Moxatag is available in tablet, extended release;oral dosage forms.
Moxatag can be used as use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes, method of treating tonsillitis and/or pharyngitis secondary to streptococcus pyogenes in a once-a-day amoxicillin product.
The generics of Moxatag are possible to be released after 07 May, 2027.
Drugs and Companies using AMOXICILLIN ingredient
Market Authorisation Date: 23 January, 2008
Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes; Method of treating tonsillitis and/or pharyngitis secondary to streptococcus pyogenes...
Dosage: TABLET, EXTENDED RELEASE;ORAL
MOXATAG family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic